Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next
From The BioCentury Show · · 36 min
This plays from the publisher's own server. We do not host a copy.
Description
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to conduct the technical diligence required for investments once considered too risky for their models. In conversation with The BioCentury Show's Stephen Hansen, Bain Capital’s Adam Koppel discussed the evolution of private equity's interest in biotech, Bain’s prioritization scheme for scaled investments and his outlook for the capital markets in the year ahead.
View full story: https://www.biocentury.com/article/657997
#PrivateEquity #BiotechDeals #LifeSciencesInvesting #GrowthEquity #BiopharmaMarkets
00:00 - Introduction 01:57 - PE's Evolution in Biotech 06:58 - Bain's Priorities 11:24 - Structuring Deals 18:23 - Capital Market Conditions 24:03 - Environment for Private Companies 27:08 - IPO Outlook